Samsung Comprehensive Cancer Center

CAR T-Cell Therapy Center

Request an Appointment
CAR-T cell

Leading the Future of Cell-Based Cancer Treatment

In 2021, Samsung Medical Center established Korea's first dedicated CAR T-Cell Therapy Center, achieving groundbreaking outcomes for patients with relapsed or refractory blood cancers. By significantly improving complete remission (CR) rates, we provide new hope for individuals facing diseases once considered untreatable.

Revolutionizing Cancer Care with CAR T-Cell Therapy

CAR T-cell therapy is offered to patients with relapsed or refractory hematologic malignancies, particularly those who have not responded to standard chemotherapy.
Eligible conditions include:
- Relapsed or refractory B-cell lymphoma targeting CD19
- Multiple myeloma targeting BCMA
- Pediatric B-lymphoblastic leukemia

CAR T-cell therapy is a highly personalized treatment in which a patient's own T cells are genetically modified to target and destroy cancer cells. These engineered T cells act with precision, attacking tumor cells that often evade normal immune surveillance. This approach offers new hope to patients with otherwise difficult-to-treat blood cancers.

Successful CAR T-cell therapy requires highly coordinated, multidisciplinary care. At Samsung Medical Center, hematologists, pediatric oncologists, ICU staff, and experts across multiple disciplines work together to design personalized, safe, and effective treatment plans tailored to each patient's unique condition.

Comprehensive CAR T-Cell Therapy Program

Our center is built on a foundation of clinical excellence, evidence-based research, and multidisciplinary collaboration. Led by highly experienced hematologists and supported by specially trained oncology nurses, we deliver individualized, coordinated care across every stage of the CAR T-cell therapy process.

Patients are managed through a dedicated CAR T-Cell Clinic, ensuring continuous monitoring before, during, and after therapy. To guarantee timely access to treatment, inpatient beds are reserved exclusively for CAR T-cell patients. Post-treatment symptoms and long-term recovery are managed through a collaborative team approach, with comprehensive patient and family education as well as structured follow-up support.